
Opinion|Videos|September 25, 2024
Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm
Author(s)Pearl Grimes, MD, FAAD
Pearl E. Grimes, MD, discusses the evolving treatment paradigm for vitiligo, highlighting the role of FDA-approved topical ruxolitinib and its impact on management strategies.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
SkinJect Advances into Registrable Development as Potential First-in-Class Therapy for Gorlin Syndrome
5










